Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 21;8(1):00701-2021.
doi: 10.1183/23120541.00701-2021. eCollection 2022 Jan.

Autoimmune pulmonary alveolar proteinosis in children

Affiliations

Autoimmune pulmonary alveolar proteinosis in children

Matthias Griese et al. ERJ Open Res. .

Abstract

In childhood, a multitude of causes lead to pulmonary alveolar proteinosis (PAP), an excessive surfactant accumulation in the alveolar space, limiting gas exchange. Autoantibodies against granulocyte-macrophage colony-stimulating factor (GM-CSF) causing autoimmune PAP, the principal aetiology in adults, are rare. In this first case series on autoimmune PAP, we detail the presentation and management issues of four children. Whereas three children presented insidiously with progressive dyspnoea, one was acutely sick with suspected pneumonia. During management, one patient was hospitalised with coronavirus disease 2019, noninvasively ventilated, and recovered. All treatment modalities known from adults including whole-lung lavage, augmentation of GM-CSF by inhaled GM-CSF, removal of neutralising antibody by plasmapheresis and interruption of antibody production using rituximab were considered; however, not all options were available at all sites. Inhaled GM-CSF appeared to be a noninvasive and comfortable therapeutic approach. The management with best benefit-to-harm ratio in autoimmune PAP is unknown and specialised physicians must select the least invasive and most effective treatment. To collect this cohort in a rare condition became feasible as patients were submitted to an appropriate registry. To accelerate the authorisation of novel treatments for autoimmune PAP, competent authorities should grant an inclusion of adolescents into trials in adults.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: M. Griese reports grants or contracts received from Böhringer Ingelheim paid to their institution; participation on a Data Safety Monitoring Board or Advisory Board for Böhringer Ingelheim, personal fees received. Unpaid Head chILD-EU; all disclosures made outside the submitted work. Conflict of interest: P. Panagiotou has nothing to disclose. Conflict of interest: E.D. Manali reports receiving grants or contracts, paid to their institution, from Hoffmann La Roche, Boehringer Ingelheim and Savara; personal payments for lectures, presentations, speakers' bureaus, manuscript writing or educational events received from Hoffmann La Roche and Boehringer Ingelheim; support for attending meetings and/or travel paid to the institution received from Hoffmann La Roche and Boehringer Ingelheim; all disclosures made outside the submitted work. Conflict of interest: M. Stahl has nothing to disclose. Conflict of interest: N. Schwerk has nothing to disclose. Conflict of interest: V. Costa has nothing to disclose. Conflict of interest: K. Douros has nothing to disclose. Conflict of interest: M. Kallieri has nothing to disclose. Conflict of interest: R.M. Urbantat has nothing to disclose. Conflict of interest: H. von Bernuth reports receiving payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from CSL Behring and Octapharma; participation on an advisory board for Takeda; and is an associate member of the Standing committee on vaccinations. All disclosures made outside the submitted work. Conflict of interest: L. Kolilekas has nothing to disclose. Conflict of interest: L. Morais has nothing to disclose. Conflict of interest: A. Ramos has nothing to disclose. Conflict of interest: K. Landwehr has nothing to disclose. Conflict of interest: K. Knoflach has nothing to disclose. Conflict of interest: F. Gothe has nothing to disclose. Conflict of interest: K. Reiter has nothing to disclose. Conflict of interest: V. Papaevangelou has nothing to disclose. Conflict of interest: A.G. Kaditis has nothing to disclose. Conflict of interest: C. Kanaka-Gantenbein has nothing to disclose. Conflict of interest: S.A. Papiris reports receiving grants or contracts paid to their institution from Hoffmann La Roche, Boehringer Ingelheim and Savara; personal payments received from Hoffmann La Roche and Boehringer Ingelheim for attending meetings and/or travel; all disclosures made outside the submitted work.

Figures

FIGURE 1
FIGURE 1
a) Autoimmune pulmonary alveolar proteinosis. Computed tomography scan of a child aged 14 years 8 months with 2 days of fever and dyspnoea. Note the ground-glass opacities and interlobar septal thickening giving the image of nonpathognomonic “crazy paving” pattern. b) Coronavirus disease 2019 pneumonia in a child aged 3 years 2 months with trisomy 21. Note the bilateral ground-glass and consolidating pattern. Both children had comparable degrees of respiratory insufficiency at the time of imaging.

References

    1. Trapnell BC, Nakata K, Bonella F, et al. . Pulmonary alveolar proteinosis. Nat Rev Dis Primers 2019; 5: 16. doi:10.1038/s41572-019-0066-3 - DOI - PubMed
    1. Griese M. Pulmonary alveolar proteinosis: a comprehensive clinical perspective. Pediatrics 2017; 140: e20170610. doi:10.1542/peds.2017-0610 - DOI - PubMed
    1. Alasiri AM, Alasbali RA, Alaqil MA, et al. . Autoimmune pulmonary alveolar proteinosis successfully treated with lung lavage in an adolescent patient: a case report. J Med Case Rep 2021; 15: 340. doi:10.1186/s13256-021-02906-2 - DOI - PMC - PubMed
    1. Feld L, Jennings J, Fiorino EK, et al. . Pulmonary alveolar proteinosis: a case of profound hypoxemia in a previously healthy teenager. Pediatr Emerg Care 2021; 37: e571–e573. doi:10.1097/PEC.0000000000001820 - DOI - PubMed
    1. Meka SG, Mohr M, Nair GB, et al. . Autoimmune pulmonary alveolar proteinosis mimicking Mycoplasma pneumonia in an adolescent. Respir Med Case Rep 2020; 30: 101100. doi: 10.1016/j.rmcr.2020.101100 - DOI - PMC - PubMed

LinkOut - more resources